Federica Ricceri

Arezzo, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 43 publications

Effectiveness of bimekizumab according to previous biologic exposure in patients with plaque psoriasis: a multicenter real-world study.

Effectiveness of bimekizumab according to previous biologic exposure in patients with plaque psoriasis: a multicenter real-world study.

Journal: The Journal of dermatological treatment

Published: July 29, 2026

Psoriasis severity, comorbidity burden, and biologic therapy: a multicenter observational study using the Charlson Comorbidity Index.

Psoriasis severity, comorbidity burden, and biologic therapy: a multicenter observational study using the Charlson Comorbidity Index.

Journal: The Journal of dermatological treatment

Published: September 24, 2025

Therapeutic Modulation Of Peripheral Blood Cells And Inflammatory Indices During 52 Weeks Of Risankizumab In Responder Patients With Moderate-to-Severe Psoriasis: Results From A Multicenter Prospective Study.

Therapeutic Modulation Of Peripheral Blood Cells And Inflammatory Indices During 52 Weeks Of Risankizumab In Responder Patients With Moderate-to-Severe Psoriasis: Results From A Multicenter Prospective Study.

Journal: Dermatology practical & conceptual

Published: August 31, 2025

Risankizumab in very elderly patients in real-world practice.

Risankizumab in very elderly patients in real-world practice.

Journal: Italian journal of dermatology and venereology

Published: November 07, 2024

Age affects drug survival rates of interleukin (IL)-17 and IL-23 inhibitors in patients with plaque psoriasis: Results from a retrospective, multicentric, multi-country, cohort study.

Age affects drug survival rates of interleukin (IL)-17 and IL-23 inhibitors in patients with plaque psoriasis: Results from a retrospective, multicentric, multi-country, cohort study.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: February 02, 2024

Efficacy of risankizumab after intra-class switching between anti IL-23 antagonists: a multi-center, retrospective, real-life observation.

Efficacy of risankizumab after intra-class switching between anti IL-23 antagonists: a multi-center, retrospective, real-life observation.

Journal: Italian journal of dermatology and venereology

Published: November 24, 2023

Real-life effectiveness of Risankizumab according to body mass index: Results of an Italian multicentre retrospective study.

Real-life effectiveness of Risankizumab according to body mass index: Results of an Italian multicentre retrospective study.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: January 24, 2023

Therapy of PsO in Special Subsets of Patients.

Therapy of PsO in Special Subsets of Patients.

Journal: Biomedicines

Published: September 29, 2022

Hidradenitis Suppurativa: The Influence of Gender, the Importance of Trigger Factors and the Implications for Patient Habits.

Hidradenitis Suppurativa: The Influence of Gender, the Importance of Trigger Factors and the Implications for Patient Habits.

Journal: Biomedicines

Published: August 16, 2022

Drug Survival of Interleukin (IL)‑17 and IL‑23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi‑country, Multicentric Cohort Study.

Drug Survival of Interleukin (IL)‑17 and IL‑23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi‑country, Multicentric Cohort Study.

Journal: American journal of clinical dermatology

Published: August 02, 2022

Tuscany consensus for the treatment of moderate-severe psoriasis: update and focus on practical guidelines for place in therapy of anti-IL-17 and anti-IL-23 biologics.

Tuscany consensus for the treatment of moderate-severe psoriasis: update and focus on practical guidelines for place in therapy of anti-IL-17 and anti-IL-23 biologics.

Journal: Italian journal of dermatology and venereology

Published: July 05, 2022

Successful use of anti-IL-23 molecules in overweight-to-obese psoriatic patients: A multicentric retrospective study.

Successful use of anti-IL-23 molecules in overweight-to-obese psoriatic patients: A multicentric retrospective study.

Journal: Dermatologic therapy

Published: June 22, 2022

Showing 1-12 of 43

Last Updated: 09/26/2026